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TObjectives: Fifty percent of human aortocoronary saphenous vein grafts are
occluded after 10 years. Intimal hyperplasia is an initial step in graft occlusion
and consists of vascular smooth muscle cell proliferation. Phosphatidylinositol
3-kinase and its downstream regulator, the inositol 3-phosphatase PTEN (phos-
phatase and tensin homolog deleted on chromosome 10), are important regula-
tors of vascular smooth muscle cell proliferation, migration, and cell death. This
study tests whether overexpression of PTEN in aortocoronary saphenous vein
grafts can reduce intimal hyperplasia.
Methods: Adult dogs underwent aortocoronary bypass grafting to the left anterior
descending artery by using the autologous saphenous vein. Saphenous vein grafts
were treated with phosphate-buffered saline (n  9), empty adenovirus (n  8), or
adenovirus encoding for PTEN (n  8). Arteriography at 30 and 90 days assessed
saphenous vein graft patency. A subset received saphenous vein grafts treated with
a marker transgene (-galactosidase, n  3), empty adenovirus (n  4), or
adenovirus encoding for PTEN (n  4) and were killed on postoperative day 3 to
confirm expression. Vascular smooth muscle cells were isolated from canine sa-
phenous vein infected with adenovirus encoding for PTEN, and immunoblotting and
proliferation assays were performed.
Results: Saphenous vein graft transgene expression was confirmed by means of
immunohistochemistry, immunoblotting, and polymerase chain reaction. Arte-
riograms revealed all saphenous vein grafts to be patent. Saphenous vein grafts
treated with adenovirus encoding for PTEN demonstrated reduced intimal area
compared with those treated with empty adenovirus and phosphate-buffered
saline (1.39  0.11 vs 2.35  0.3 and 2.57  0.4 mm2, P  .05), and the
intima/media ratio was lower in saphenous vein grafts treated with adenovirus
encoding for PTEN (0.50  0.05 vs 1.43  0.18 and 1.11  0.14, P  .005).
PTEN overexpression in vascular smooth muscle cells inhibited platelet-derived
growth factor–induced phosphorylation of Akt, a downstream effector of phos-
phatidylinositol 3-kinase. PTEN-treated vascular smooth muscle cells demon-
strated decreased basal, platelet-derived growth factor–stimulated, and serum-
stimulated proliferation.
Conclusion: This study demonstrates that PTEN overexpression in aortocoronary
saphenous vein grafts reduces intimal hyperplasia. The mechanism of this
antiproliferative effect in vascular smooth muscle cells is likely due to inhibition
of phosphatidylinositol 3-kinase signaling through Akt, with resultant decreases
in vascular smooth muscle cell growth and survival. Therefore modulation of the
phosphatidylinositol 3-kinase pathway through PTEN overexpression might
represent a novel therapy to prevent saphenous vein graft intimal hyperplasia
after coronary artery bypass grafting.
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CSPSaphenous vein grafts (SVGs) represent the most com-mon conduit used for surgical revascularization pro-cedures, including coronary artery bypass grafting
(CABG). Unfortunately, long-term aortocoronary SVG ef-
ficacy is limited by intimal hyperplasia (IH) and subsequent
accelerated atherosclerosis, resulting in a 10-year graft fail-
ure rate approaching 50%.1 Current attempts to limit SVG
stenosis include technical considerations, antiplatelet ther-
apy, and lipid-lowering medications.2,3 Despite these inter-
ventions, SVG failure after CABG remains a difficult prob-
lem, leading to recurrent angina and a 10% to 15%
incidence of redo CABG.
IH begins early after vein graft implantation and can
eventually lead to luminal stenosis and occlusion. IH is
characterized by abnormal migration of vascular smooth
muscle cells (VSMCs) from the media to the intima.
VSMCs subsequently proliferate and undergo hypertrophy,
with associated deposition of an extracellular connective
tissue matrix.4 Although not completely characterized, these
pathologic changes are caused by the release of mitogenic
growth factors in the setting of vascular injury.5 Many
growth factors and hormones can trigger IH by activating
phosphatidylinositol (PI) 3-kinase in VSMCs. PI 3-kinase is
a lipid kinase that phosphorylates phosphatidylinositol at
the D-3 position of the inositol ring, and the resulting
products, PI 3,4-bisphosphate (PI 3,4-P2) and PI 3,4,5-
trisphosphate (PIP3), are potent signaling molecules that
regulate cell proliferation, migration, and survival.6 Re-
cently, the drug sirolimus (rapamycin), which inhibits a
downstream effector of PI 3-kinase (mammalian target of
rapamycin [mTOR]), has shown promising results in the
prevention of in-stent restenosis.7 In addition to mTOR,
however, PI 3-kinase activates many other effectors, such as
extracellular signal–regulated kinase (ERK) and Akt, which
associate with membrane-bound 3-phosphoinositides and
have been implicated as key mediators of cell growth,
proliferation, and survival.8 Taken together, these studies
implicate PI 3-kinase as a potential upstream regulator of
these processes, leading to the hypothesis that inhibition of
PI 3-kinase signaling might produce potent effects on IH.
Recent studies have investigated this hypothesis by using
an endogenous inhibitor of PI 3-kinase in VSMCs.9,10
PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) is an inositol 3-phosphatase that was originally
characterized as a tumor suppressor protein. PTEN hydro-
lyzes the 3-phosphoinositide lipid products of PI 3-kinase,
PI 3,4-P2, and PIP3, preventing downstream activation of
PI 3-kinase effector molecules. Adenovirus-mediated ex-
pression of PTEN in rabbit VSMCs inhibited platelet-de-
rived growth factor (PDGF)–induced cellular proliferation,
migration, and survival, suggesting that in vivo overexpres-
sion of PTEN might prevent the formation of IH.9
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steps, the effectiveness of PTEN to inhibit SVG IH has not
yet been examined in a clinically relevant, large-animal
model. Previously, we characterized a canine model of
aortocoronary SVG IH and demonstrated efficient transgene
expression by using ex vivo delivery of adenoviral vec-
tors.11 This study tests the hypothesis that treatment of
aortocoronary SVGs with an adenoviral vector encoding the
PTEN transgene can limit IH. Additionally, we investigate
the effects of PTEN overexpression in cultured canine sa-
phenous vein (SV) smooth muscle cells.
Methods
Experimental Design
Animals used in this study were mongrel dogs (n  36; weight,
27-32 kg). As previously described, each dog underwent CABG
with a reversed SVG from the aorta to the left anterior descending
artery (LAD).11 Before grafting, veins were treated with 5  1011
total virus particles of either an adenovirus encoding for PTEN
(AdPTEN; n  8) or empty adenovirus (AdEV; n  8). A third
group of dogs were sham-infected by means of treatment of the
SVG with phosphate-buffered saline (PBS; n  9). SVG patency
was confirmed by arteriograms performed on postoperative days
(PODs) 30 and 90. Dogs were subsequently euthanized, and the
SVGs were harvested.
A subset of dogs received SVGs treated with the marker
transgene -galactosidase (Adgal; n  3) and were killed on
POD 3 to confirm transgene expression. Another subset of dogs
treated with AdPTEN (n 4) or AdEV (n 4) was killed on POD
3 for histologic analysis.
All animal procedures were humanely performed in accordance
with regulations adopted by the National Institutes of Health and
approved by the Animal Care and Use Committee of Duke
University.
Adenovirus Construction
The structure of a recombinant, replication-deficient adenovirus
directing the expression of wild-type human PTEN (AdPTEN) has
been described previously.10 Control viruses were also con-
structed, including an empty adenovirus containing no cDNA
insert (AdEV), and adenoviruses containing the coding sequence
for -galactosidase (Adgal) and the green fluorescent protein
(AdGFP). Adenoviruses were amplified on HEK-293 cells and
purified by means of ultracentrifugation on a CsCl density gradi-
ent, as previously described.10 The procedures and handling of
animals and tissues exposed to recombinant adenovirus were ap-
proved by the Institutional Biosafety Committee of Duke Univer-
sity in compliance with guidelines from the National Institutes of
Health.
Operative Protocol
SV harvest, SVG gene delivery, and CABG were performed as
previously described.11 Briefly, each dog was sedated, intu-
bated, and heparinized (100 U/kg). Ten centimeters of SV was
harvested from the hind leg. For the AdPTEN- or AdEV-treated
groups, 5  1011 total virus particles were suspended in 1 mL
of PBS. The adenoviral solution was delivered to the SV
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Pintraluminally with a measured distension pressure of 10 mm
Hg for 20 to 30 minutes. For the PBS group, the SV was flushed
only. A partial lower sternotomy was performed, and an end-
to-side anastomosis was performed between the SVG and the
ascending aorta. By using a myocardial stabilizer (Guidant), an
end-to-side anastomosis was performed between the SVG and
the distal LAD. The proximal LAD was subsequently ligated,
rendering the anterior left ventricle SVG-dependent. An ultra-
sonic vascular probe (Transonic Systems) confirmed SVG flow.
Dogs were maintained on buffered aspirin (325 mg/d) through-
out the protocol.
Arteriographic Confirmation of SVG Patency
On PODs 30 and 90, the dogs underwent coronary arteriography.
A 6F coronary catheter was placed into the left coronary artery
under fluoroscopic guidance, and radio-opaque dye was used to
confirm the patency of the SVG.
Tissue Preparation and Histologic Analysis
At the time of death, tissues were harvested, including SVGs,
nongrafted SV, left and right ventricles, livers, and lungs. Hema-
toxylin and eosin and X-gal staining were performed using stan-
dard techniques.12 An anti-PTEN monoclonal antibody (clone
A2B1, Santa Cruz Biotech) was used to immunostain for PTEN
expression.
In a subset of dogs (n  3), short segments of AdPTEN-
infected SV were cultured for 3 days, and PTEN expression was
assessed by means of immunoblotting.
Morphologic Analysis
Five-micrometer transverse vessel sections were stained with
hematoxylin and eosin, and measurements were made with
Image Tool version 3.0 (The University of Texas Health Sci-
ences Center, San Antonio), as previously described.11 For each
dog, 3 sections from each third of the SVG were analyzed, and
the intimal area, medial area, and maximal-minimal wall thick-
ness were quantified. The ratio of the intimal to meldial area was
calculated.
DNA Isolation and PCR
Tissue was incubated in lysis buffer (100 mmol/L Tris/HCl, 5
mmol/L ethylenediamine tetraacetic acid, 0.2% sodium dodecyl-
sulfate, 200 mmol/L NaCl, and 0.2 mg/mL Proteinase K [Sigma]).
The supernatant was extracted, and the DNA was precipitated. A
polymerase chain reaction (PCR) was performed using a forward
primer specific for the cytomegalovirus promoter and a reverse
primer specific for human PTEN.
Cell Harvest and Culture
VSMCs were isolated from canine SVs harvested under sterile
conditions. Briefly, the adventitia was stripped away, and the
intima was removed by means of blunt dissection. The media
was cut into 1-cm2 sections and placed in culture dishes con-
taining a small amount of growth medium, as previously de-
scribed.13 After 10 days, veins were removed, and monolayers
of smooth muscle cells were trypsinized and passaged. In this
study, only cells between passages 3 and 5 were used.
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VSMCs were grown in Dulbecco’s modified Eagle’s medium/
F12 HAM containing 10% fetal bovine serum (FBS). When the
cells were nearly confluent, the medium was changed to 2%
FBS, and virus vectors were added at a multiplicity of infection
of 100. After 24 hours, the medium was changed to serum-free
medium, followed by different treatments or stimuli as indi-
cated. As a control in all experiments, an identical group of
cells was left uninfected.
Immunoblotting
After infection with adenoviruses, VSMCs were serum starved for
5 hours and then stimulated for 5 minutes with PDGF (20 ng/mL,
R&D Systems). Cells were lysed, and samples were separated by
means of sodium dodecylsulfate 8% to 16% polyacrylamide gel
electrophoresis.14 Membranes were Western blotted with the fol-
lowing antibodies: anti-PTEN monoclonal antibody (clone A2B1,
Santa Cruz Biotech); anti-phospho-Akt (Ser473), anti-Akt, anti-
phospho-p44/42 ERK (Thr202/Tyr204), and anti-p44/42 ERK
(Cell Signaling Tech); and rat monoclonal anti--tubulin (clone
YL1/2, Abcam).
Thymidine Incorporation and Cell Counts
Tritiated thymidine incorporation was assayed, as previously de-
scribed,10 to evaluate the effect of PTEN overexpression on
PDGF-mediated DNA synthesis in VSMCs. Briefly, VSMCs were
plated and either left uninfected or infected with AdPTEN or
AdGFP. The cells were pulse labeled with tritiated thymidine (2
Ci/mL, Amersham-Pharmacia Biotech) for 3 hours, and thymi-
dine incorporation was assessed by means of liquid scintillation
counting.
For cell counts, VSMCs were plated in triplicate on 12-well
plates and either left uninfected or infected with AdPTEN or
AdGFP. The medium was changed to serum-free medium, and the
cells were incubated for 48 hours with or without PDGF (20
ng/mL) or FBS (5%). The cells were trypsinized and counted on a
hemacytometer (Fisher).
Statistical Analysis
All data are represented as the mean  standard error of the mean.
Statistical significance was determined by means of 1-way analysis
of variance. Pairwise comparisons were then made with the Bon-
ferroni or Student-Newman-Keuls post-hoc tests.
Results
Assessment of SVG Patency
SVGs from all dogs in this study (n  36) were confirmed
to be patent immediately after completion of the distal
anastomosis with an ultrasonic vascular flow probe. All
flows were greater than 25 mL/min. Two dogs (both control
group) died within 72 hours postoperatively and were ex-
cluded from the study. All of the remaining dogs in the
90-day cohort (n  25) survived to POD 90 and were
included in the analysis. Arteriograms obtained on PODs 30
and 90 demonstrated all SVGs to be patent. Qualitative
analysis revealed extensive filling defects consistent with
graft wall thickening throughout the PBS and AdEV-treated
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defects (data not shown).
Assessment of Transgene Expression
In Adgal- and AdPTEN-treated SVGs explanted on POD
3, transgene expression was confirmed on the basis of
histologic staining (Figure 1, A-D). Transgene expression
was robust and circumferential in the intima, with more
diffuse expression throughout the media. In SVs undergoing
adenoviral infection followed by 3 days of in vitro culture,
Western blotting revealed marked PTEN expression com-
pared with that seen in uninfected veins (data not shown).
PCR analysis was performed on total DNA isolated from
SVG, normal SV, left and right ventricular myocardium,
liver, and lung samples from AdPTEN-treated dogs killed
on POD 3 (n  4). The primers used were specific for the
adenoviral PTEN transgene. The PTEN transgene DNA was
detected in all SVG samples, and normal SVs from the same
dogs served as negative controls (Figure 1, E). Similar
tissue was harvested from AdEV-treated dogs (n  4) and
demonstrated no evidence of PTEN transgene expression
(Figure 1, E). Additionally, left and right ventricular myo-
cardium, liver, and lung samples from the AdPTEN-treated
dogs demonstrated no evidence of transgene expression
(data not shown).
Quantification of Intimal Hyperplasia
AdPTEN-treated SVGs demonstrated reduced intimal area
compared with AdEV- and PBS-treated grafts (1.39  0.11
vs 2.35  0.3 and 2.57  0.4 mm2; P  .05, analysis of
variance with Student-Newman-Keuls test; Figure 2 and
Table 1). Additionally, the intima/media ratio was lower in
AdPTEN-treated SVGs compared with that in AdEV- and
PBS-treated grafts (0.50  0.05 vs 1.43  0.18 and 1.11 
0.14, P  .005). Medial area and maximum-minimum wall
thickness were not significantly different among groups.
Representative photomicrographs of SVGs from each group
and a normal SV are shown in Figure 2.
VSMC Signaling and Proliferation
VSMCs were cultured from canine SVs and infected with
recombinant adenoviruses expressing wild-type PTEN
(AdPTEN) or GFP (AdGFP) to investigate the mechanism
of action of AdPTEN in SVGs. As an additional control,
uninfected cells were evaluated in an identical manner.
Cells were then treated with PDGF to induce cellular pro-
liferation. Although PTEN is expressed endogenously in
canine VSMCs, AdPTEN infection induced significant
overexpression (Figure 3). Treatment of canine uninfected
or AdGFP-infected VSMCs with PDGF induced phosphor-
ylation of Akt, which correlates with Akt activation (Figure
3). Overexpression of PTEN blocked PDGF-induced phos-
phorylation of Akt in VSMCs (Figure 3). Likewise, PDGF
1408 The Journal of Thoracic and Cardiovascular Surgery ● Junstimulation of uninfected or AdGFP-infected VSMCs in-
creased phosphorylation of ERK. However, overexpression
of PTEN did not inhibit ERK phosphorylation. These re-
sults suggest that the effects of PTEN on VSMC growth are
mediated in part by inhibition of Akt but not ERK.
We next investigated whether the effects of PTEN over-
expression on PI 3-kinase–mediated signaling pathways
correlated with cellular responses relevant to the process of
IH. Canine SV VSMCs were infected with AdPTEN,
AdGFP, or left uninfected. PDGF- and FBS-stimulated
DNA synthesis was measured by means of tritiated thymi-
dine incorporation. PDGF induced significant increases in
DNA synthesis in uninfected and AdGFP-infected VSMCs
(Figure 4, A). PTEN overexpression significantly decreased
basal thymidine incorporation, as well as in response to
PDGF and FBS (Figure 4, A).
Cell counts were performed on uninfected and AdGFP-
or AdPTEN-infected VSMCs treated with or without PDGF
or FBS to confirm these findings. Both PDGF and FBS
induced a significant increase in the number of uninfected or
AdGFP-infected canine VSMCs (Figure 4, B). PTEN over-
expression significantly decreased the number of unstimu-
lated cells compared with AdGFP-infected or uninfected
cells. PTEN overexpression also inhibited both PDGF- and
FBS-stimulated increases in cell number (Figure 4, B).
Together, these findings demonstrate that PTEN overex-
pression blocks PDGF- and FBS-mediated increases in
VSMC proliferation.
Discussion
Pathologic VSMC proliferation and associated IH is a crit-
ical early factor leading to aortocoronary SVG failure.15 PI
3-kinase plays a central role in this process through its
3-phosphoinositide lipid products, PI(3,4)P2 and PIP3,
which regulate the activation of downstream effector mol-
ecules, including Akt and mTOR.6 Specifically, Akt is re-
cruited to and associates with the plasma membrane–bound
3-phosphoinositides. Akt subsequently activates mTOR,
which in turn phosphorylates key ribosomal proteins in-
volved in cell protein translation.14 As a result, hydrolysis of
PI(3,4)P2 and PIP3 by PTEN, an inositol phosphatase spe-
cific for these lipid products, would be expected to inhibit
the cellular processes required for IH.
In this study we tested the effects of inhibiting PI 3-ki-
nase–mediated signaling by overexpressing the inositol
3-phosphatase PTEN through adenovirus-mediated gene
transfer in a large-animal model of aortocoronary SVG IH.
Indeed, SVGs treated with AdPTEN demonstrated an ap-
proximately 50% reduction in intimal area relative to saline
and AdEV-infected control SVGs 90 days after grafting.
This was accompanied by a significant decrease in the
intima/media ratio. PTEN overexpression in vitro in canine
SV VSMCs led to inhibition of an important effector of PI
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P3-kinase, Akt. Moreover, PTEN overexpression signifi-
cantly inhibited both basal and PDGF-induced VSMC pro-
liferation. Together, these results suggest that PTEN over-
expression might have a therapeutic role in preventing IH
after vascular interventions, such as CABG.
The canine model of aortocoronary SVG IH used in this
study was first characterized by Brody and colleagues16,17
and Silver and associates.18 These studies demonstrated that
histologic changes closely resembling those seen in human
aortocoronary SVGs, including medial fibrosis and IH, oc-
curred within the first month after surgical intervention. We
further characterized this canine model and demonstrated
that by POD 90, the intimal area and the intima/media ratio
Figure 1. Adenovirus-mediated overexpression of transgenes in
canine aortocoronary SVGs. Representative sections (10 m)
from SVGs explanted on POD 3 are shown. A, Uninfected control
(Xgal stain); B, Adgal-infected (X-gal stain, gal  blue); C,
AdEV-infected (anti-PTEN stain, PTEN  red); and D, AdPTEN-
infected (anti-PTEN stain, PTEN  red). E, PCR analysis per-
formed on SVGs explanted on POD 3: expression of the PTEN
transgene in AdPTEN- or AdEV-infected SVGs (VG) versus normal
vein (NV). , Positive control; , negative control.were dramatically increased in SVGs compared with un-
The Journal of Thoracicgrafted veins.11 Furthermore, careful histologic analysis of
the vein grafts demonstrated that the IH occurred along the
entire length of the grafted vessel. Although this model does
not completely mimic human vein graft hyperplasia in that
it lacks underlying atherosclerotic accumulation of foam
cells or lipid deposits, we believe it represents the most
relevant preclinical model in which to test potential thera-
pies. Appropriate caution should be exercised, however, in
extrapolating the results of this relatively short-term, large-
animal model to the chronic, multifactorial disease process
that occurs in human SVG failure.
We and other groups have demonstrated that an ex vivo
adenoviral delivery technique can produce efficient trans-
gene expression in aortocoronary SVGs.11,19 The current
study used this technique to successfully deliver a poten-
tially therapeutic transgene to aortocoronary SVGs, result-
ing in dramatic inhibition of IH. In addition to PTEN,
several other targets have shown promise for the prevention
of IH. Cable and coworkers20 demonstrated that adenovirus-
mediated overexpression of nitric oxide synthase signifi-
cantly reduced IH in cultured human SVGs. Similar results
were obtained after overexpression of tissue inhibitors of
matrix metalloproteinases.21 Using a nonviral delivery
method, Shitani and colleagues22 demonstrated that pres-
sure-mediated transfection of decoy oligonucleotides of nu-
clear factor B resulted in decreased IH after 4 weeks in a
canine aortocoronary SVG model similar to that used in this
Figure 2. PTEN overexpression inhibits IH. Representative hema-
toxylin and eosin–stained sections of normal SVG (A), PBS-
treated SVG (B), AdEV-treated SVG (C), and AdPTEN-treated SVG
(D) from animals killed on POD 90. Arrows indicate intimal
borders (scale  1 mm).study. Most importantly, the efficacy of E2F decoy oligo-
and Cardiovascular Surgery ● Volume 129, Number 6 1409
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resulted in the first clinical trial of human aortocoronary
SVG gene therapy (PREVENT IV), which is currently
underway. Taken together, these studies suggest that SVG
IH is a multifactorial process that has yet to be fully char-
acterized and for which several therapies in combination
might prove to be the most efficacious.
The results of this study highlight several issues related
to extending adenovirus-mediated delivery techniques to
clinical vascular gene therapy. Although significant inhibi-
tion of IH was observed up to 90 days postoperatively, the
typical duration of transgene expression with first-genera-
tion adenoviral vectors, such as that used here, is typically
Figure 3. Overexpression of PTEN inhibits Akt phosphorylation in
canine SV VSMCs. Lysates from VSMCs infected with the indi-
cated adenoviruses and treated with or without PDGF (20 ng/mL)
for 5 minutes were Western blotted sequentially with antibodies
specific for PTEN, phospho-Akt (pAkt), and phospho-ERK (pERK).
Equal protein loading was confirmed with antibodies against
total Akt, total ERK, and -tubulin. Similar results were observed
in 6 different experiments. Un, Uninfected; GFP, green fluorescent
TABLE 1. Morphologic analysis of canine SVGs 90 days a
Saline (n  9)
Intimal area (mm2) 2.57 0.4
Medial area (mm2) 2.28 0.22
I/M ratio 1.11 0.14
Maximum wall thickness (mm) 1.64 0.29
Minimum wall thickness (mm) 0.65 0.06
Saphenous vein grafts were treated ex vivo with adenovirus encoding for P
AdPTEN, adenovirus encoding for PTEN; I/M ratio, intimal/medial ratio. *P
of variance ([Student-Newman-Keuls test]).protein.
1410 The Journal of Thoracic and Cardiovascular Surgery ● Junless than 3 weeks. This suggests that inhibition of molecular
triggering mechanisms early after vascular injury might be
sufficient to produce intermediate or long-term beneficial
effects. A potential explanation for this effect is that inhi-
bition of VSMC proliferation is required only until the
damaged vessel endothelium can be regenerated. If this
hypothesis is true, adenoviral vectors might be ideal for
vascular gene therapy because their limited length of action
would avoid the possibility of long-term toxicity. This is
especially relevant to transgenes with a proapoptotic mech-
anism, such as PTEN, in which chronic expression might
prove deleterious. Additionally, future studies need to be
performed to assess the efficacy of this method in prevent-
ing long-term IH. Clearly, the robust IH seen in this canine
model occurs more rapidly than that typically seen in human
subjects, and although the reasons for this remain unclear, it
represents a major limitation of this study. However, the
ability of transgenes such as PTEN to attenuate IH up to 3
months postoperatively suggests that such techniques might
hold promise for the clinical arena.
Another important advantage of potential clinical vascu-
lar gene therapy is local delivery. In this study the adeno-
virus is delivered with an ex vivo method confined solely to
the vessel and occurring during the natural course of a
bypass operation. As expected with this technique, PTEN
transgene expression limited to the SVG was not observed
in any other tissues, including left ventricular myocardium
perfused by the implanted graft. Treatment of harvested or
artificial vascular conduits before implantation might rep-
resent the most safe and clinically applicable approach with
which to attempt human vascular gene therapy.
In this study transgene expression in the SVGs was
assessed using several different methods, including immu-
noblotting, histologic staining, and PCR. To initially con-
firm the expression of PTEN using the ex vivo delivery
method, we performed immunoblotting on infected SVGs
after 3 days of in vitro culture (data not shown). In the
immunostained sections of AdEV-infected veins, low levels
of endogenous PTEN were visible, and endogenous PTEN
was readily detectable in cultured canine VSMCs. PTEN is
CABG
EV (n  8) AdPTEN (n  8) P value*
2.53 0.3 1.39 0.11 .05
1.95 0.48 2.8  0.13 NS
1.43 0.18 0.50 0.05 .005
1.42 0.15 1.16 0.06 NS
0.72 0.07 0.62 0.03 NS
(5  1011 particles) versus empty virus or saline controls. EV, Empty virus;
e: adenovirus encoding for PTEN versus saline and empty virus (analysisfter
TEN
valuhighly homologous across species, both at the DNA and
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Pprotein levels. Because of the ubiquitous expression of
PTEN throughout body tissues, we modified our PCR tech-
nique to achieve specificity for the adenoviral PTEN trans-
gene. This was accomplished by using a forward primer
specific for the adenoviral vector’s cytomegalovirus pro-
moter and a reverse primer specific for human PTEN, pro-
ducing a very specific and sensitive test for the PTEN
transgene.
The effect of PTEN on the molecular and cellular re-
sponses of VSMCs was evaluated in the presence of 2
stimulants, PDGF and FBS. As a smooth muscle growth
factor, PDGF is a powerful VSMC mitogen and survival
factor that is released during arterial injury and contributes
to IH.24-26 In contrast, serum contains a host of other growth
factors and hormones, which are also known to activate PI
3-kinase and its downstream effectors. The observed ability
of PTEN to attenuate VSMC responses to both PDGF and
FBS at a cellular level suggests a potential mechanism for
the observed in vivo effects. However, there are undoubt-
edly many mechanisms involved in the process of SVG IH
that do not involve smooth muscle cell inhibition and are
therefore unaffected by PTEN overexpression.
It is likely that the observed inhibition of VSMC prolif-
eration by PTEN was mediated in part by an increase in
apoptosis, an effect that has been demonstrated previously
in arterial VSMCs.9 Serum starvation induced only moder-
ate cell loss in the canine VSMCs, whereas a significant
decrease in cell number was observed in PTEN-expressing
cells, even in the presence of PDGF or FBS. Accordingly,
PTEN overexpression markedly inhibited activation of Akt,
a critical regulator of cell survival. Thus we postulate that
some of the antiproliferative effects of PTEN overexpres-
sion were due to enhanced cell death. Further studies, in-
cluding direct measures of saphenous VSMC apoptosis, are
needed to confirm this hypothesis.
Importantly, the proliferative response of AdPTEN-in-
fected cells to PDGF or FBS was significantly inhibited,
suggesting that the effects of PTEN were not solely due to
apoptosis but that PTEN also blocked a specific prolifera-
tive pathway. PI 3-kinase signaling has been linked to
cellular proliferation in a variety of cell types, which has
been associated with activation of both ERK and Akt.27 PI
3-kinase has been shown to be either upstream or down-
stream of ERK and to be activated through a parallel or
independent pathway.28,29 In this study overexpression of
PTEN, which inhibits all PI 3-phosphoinositide–dependent
signaling, inhibited activation of Akt but not ERK. This
finding is consistent with previous results in endothelial and
arterial VSMCs, in which PTEN overexpression did not
alter ERK activation.9 These findings demonstrate that
PTEN and PI 3-kinase are not upstream of ERK in the
canine VSMCs used in this study.
The Journal of ThoracicIn addition to being activated by many types of cellular
receptors, PI 3-kinase is ubiquitously expressed in tissues
throughout the body. As a result, systemic inhibition of PI
3-kinase by PTEN would likely cause serious toxicity, po-
tentially mimicking the chemotherapeutic effects of drugs
such as rapamycin, which targets the PI 3-kinase down-
stream effector mTOR. However, just as local delivery of
rapamycin in coated stents has yielded positive early results,
local expression of a transgene such as PTEN might be
clinically desirable. Indeed, in targeting the phospholipid
products of PI 3-kinase, PTEN is proximal to effectors such
Figure 4. PTEN inhibits canine SV VSMC proliferation. A, VSMCs
were either uninfected (Un) or infected with AdPTEN or AdGFP,
quiesced in serum-free medium for 24 hours, treated with or
without PDGF (20 ng/mL) or FBS (5%) for 18 hours, and then pulse
labeled with tritiated thymidine. Thymidine incorporation was
assessed by uninfected scintillation counting of precipitated DNA
(n 3 assays performed in triplicate). P< .05 versus uninfected
and GFP unstimulated VSMCs (-); *P < .05 versus uninfected and
GFP PDGF-stimulated VSMCs; #P< .01 versus uninfected and GFP
FBS-stimulated VSMCs (analysis of variance, Bonferroni post-hoc
test). B, VSMCs were treated as in A, except cells were grown for
48 hours in serum-free media or in the presence of PDGF or FBS.
Then cells were trypsinized and counted (n 5 assays performed
in triplicate). †P < .05 versus GFP-stimulated VSMCs (-); *P < .01
versus uninfected or GFP PDGF-stimulated VSMCs; #P < .001
versus uninfected or GFP FBS-stimulated VSMCs.as mTOR and Akt in this signaling pathway. Therefore
and Cardiovascular Surgery ● Volume 129, Number 6 1411
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CSPPTEN overexpression should inhibit the entire cascade of
downstream PI 3-kinase effectors, potentially yielding a
more potent inhibitory effect on IH.
Conclusion
This study demonstrates that adenovirus-mediated expres-
sion of PTEN inhibits aortocoronary SVG IH in a large-
animal model. This antiproliferative effect is mediated in
canine and human VSMCs through inhibition of PI 3-kinase
signaling. These results suggest that modulation of the PI
3-kinase pathway through PTEN overexpression might rep-
resent a novel therapy to prevent IH in vascular conduits,
such as aortocoronary SVGs.
Addendum
A recently published study from our group30 demonstrated
that adenovirus-mediated overexpression of PTEN in a ca-
rotid arterial injury model significantly inhibited neointimal
hyperplasia, in part due to an increase in medial cell apo-
ptosis. Together, these findings suggest that delivery of
PTEN to the vessel wall may have similar effects in differ-
ent vascular injury states, such as restenosis following per-
cutaneous vascular interventions and CABG.
We thank George Quick, Ronald Johnson, Elaine Parker, and
Mike Lowe for their valuable technical support during all animal
procedures in this study and Damian Craig for statistical assis-
tance.
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Discussion
Dr Michael Mann (San Francisco, Calif). First of all, I would like
to commend you and your group on carrying the torch for vascular
gene therapy in these dark days when most card-carrying gene
therapists have to travel incognito, but I do have a couple of
questions for you.
e 2005
Hata et al Cardiopulmonary Support and PhysiologyPTEN, of course, being an intracellular enzymatic target, in this
case for gene transfer, one would expect to depend on a very high,
in this case, transduction efficiency or infection efficiency with the
virus to hit a large population of the target smooth muscle cells that
you are trying to inhibit. It looks like you very carefully repro-
duced previous data that had shown that the type of infection that
you do is fairly effective at getting the intima, probably a lot of the
endothelial cells, but not really very effective, probably less than
10%, of the medial smooth muscle cells, which are actually your
target.
I wonder whether you have thought about 2 things: (1) how you
explain a measurable and even somewhat significant effect on IH
through an intracellular target that allows you to only hit a very
small percentage of your target cells and (2) whether you consid-
ered using alternative viruses, such as an adeno-associated virus,
that at least in some people’s hand has been better at getting across
the internal elastic lamina?
Dr Hata. Thank you, Dr Mann, for your comments and ques-
tions. In terms of the intima versus media infectivity, you are
absolutely correct, we would want to get infection of both layers,
especially the VSMCs, before they are able to migrate into the
intima and become the neointima. In our histologic sections of
treated veins, we see expression in both layers. There is clearly
robust expression in the intima, but we also see significant viral
penetration into the media. As our results demonstrate, the result-
ing transgene expression in both layers is enough to effectively
stop the migration and proliferation of VSMCs and the develop-
ment of IH.
In terms of other viruses that you mentioned, we are very
interested, as most gene therapists are, in using improved vectors,
because we believe this is currently one of the major limitations of
the field. For example, we are in the process of obtaining and
delivering adeno-associated viruses containing both marker genes
and target transgenes, and those studies are ongoing.
Dr Robert C. Robbins (Stanford, Calif). You showed us nice
data on cell proliferation and alluded to the potential of a mech-
anistic effect of this treatment on apoptosis, but you did not show
The Journal of Thoracicus any data either in the article or in your presentation about
apoptosis. What comment do you have about that?
Dr Hata. Prior studies by Kontos and associates have demon-
strated that the action of PTEN in other types of VSMCs occurs in
part by promoting apoptosis. Similar studies are ongoing to verify
this mechanism in our model, both in vitro with isolated VSMCs
and in the whole-vein sections. It will be interesting to see whether
the results will be similar in our model of SVG IH to what has been
demonstrated in other settings, such as arterial injury and resteno-
sis.
Dr Robbins. When we have tried to look at IH in vein grafts,
it is not like an artery that has an internal elastic membrane there,
so what was your borderline for the IH in calculating your area and
your intima/media ratio?
Dr Hata. I agree that it can be difficult to delineate each layer
in the vein wall. On our sections we attempted to define the
intima-media border as clearly as possible. In most sections we
were able to determine where the circular muscle cells of the
medial layer started and use that as our borderline.
Dr Ross M. Ungerleider (Portland, Ore). What do you predict
would be the duration of this effect if you just pushed the time to
proliferation off by several months and eventually we end up in the
same place with this kind of treatment?
Dr Hata. An excellent question, and at this time, we do not
know the answer. We examined the grafts after 90 days, which we
had earlier demonstrated to be a reasonable period of time in this
canine model for IH to develop. We have some dogs that we are
keeping alive to 1 year, at which time we are going to perform
similar arteriographic and histologic analyses. We do know that
the transgene is only expressed for 2 or 3 weeks at most with this
type of adenovirus. Therefore we hypothesize that an important
part of the development of IH in these grafts is an early vascular
injury event. The ability to block these early triggering mecha-
nisms in this study led to inhibition of hyperplasia up to 90 days,
but we hope to demonstrate in subsequent studies that this effect
lasts even longer.
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